MA33434B1 - Treatment of hot flashes of symptoms and night sweats with precursors of sexual steroids with selective estrogen receptor modifiers - Google Patents

Treatment of hot flashes of symptoms and night sweats with precursors of sexual steroids with selective estrogen receptor modifiers

Info

Publication number
MA33434B1
MA33434B1 MA34540A MA34540A MA33434B1 MA 33434 B1 MA33434 B1 MA 33434B1 MA 34540 A MA34540 A MA 34540A MA 34540 A MA34540 A MA 34540A MA 33434 B1 MA33434 B1 MA 33434B1
Authority
MA
Morocco
Prior art keywords
symptoms
precursors
treatment
loss
administration
Prior art date
Application number
MA34540A
Other languages
Arabic (ar)
French (fr)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43306950&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33434(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of MA33434B1 publication Critical patent/MA33434B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION PORTE SUR DE NOUVEAUX PROCÉDÉS POUR LA RÉDUCTION OU L'ÉLIMINATION DE L'INCIDENCE DE BOUFFÉES DE CHALEUR, DE SYMPTÔMES VASOMOTEURS ET DE SUEURS NOCTURNES TOUT EN DIMINUANT LE RISQUE D'ACQUÉRIR UN CANCER DU SEIN, DE L'UTÉRUS OU DE L'ENDOMÈTRE ET EN PRÉSENTANT DE PLUS UN EFFET BÉNÉFIQUE PAR L'INHIBITION DU DÉVELOPPEMENT DE L'OSTÉOPOROSE, DE L'HYPERCHOLESTÉROLÉMIE, DE L'HYPERLIPIDÉMIE, DE L'ATHÉROSCLÉROSE, DE L'HYPERTENSION, DE LA RÉSISTANCE À L'INSULINE, DU DIABÈTE DE TYPE 2, DE LA PERTE DE MASSE MUSCULAIRE, DE L'ADIPOSITÉ, DE LA MALADIE D'ALZHEIMER, DE LA PERTE DE COGNITION, DE LA PERTE DE MÉMOIRE OU DE LA SÉCHERESSE VAGINALE CHEZ DES ANIMAUX À SANG CHAUD SUSCEPTIBLES, COMPRENANT LES ÊTRES HUMAINS, QUI ENTRAÎNE L'ADMINISTRATION D'UNE CERTAINE QUANTITÉ D'UN PRÉCURSEUR DE STÉROÏDE SEXUEL, EN PARTICULIER LA DÉHYDROÉPIANDROSTÉRONE (DHEA) ET UN ANTI-'STROGÈNE OU UN MODULATEUR SÉLECTIF DU RÉCEPTEUR DE L''STROGÈNE SÉLECTIF, EN PARTICULIER DES COMPOSÉS BENZOPYRANES. L'INVENTION PORTE ÉGALEMENT SUR DES COMPOSITIONS PHARMACEUTIQUES DESTINÉES À L'ADMINISTRATION D'UN OU DE PLUSIEURS AGENTS ACTIFS ET SUR UN OU PLUSIEURS NÉCESSAIRES UTILES À L'INVENTION.THE INVENTION HAS INVOLVED IN NEW METHODS FOR REDUCING OR ELIMINATING THE INCIDENCE OF HEAT BURNS, VASOMOTOR SYMPTOMS AND NOCTURNAL SWEATERS WHILE REDUCING THE RISK OF ACQUIRING BREAST CANCER, UTERUS OR THE ENDOMETER AND WHILE PRESENTING A BENEFIT EFFECT BY INHIBITING THE DEVELOPMENT OF OSTEOPOROSIS, HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA, ATHEROSCLEROSIS, HYPERTENSION, RESISTANCE TO INSULIN, TYPE 2 DIABETES, MUSCLE MASS LOSS, ADIPOSITY, ALZHEIMER'S DISEASE, COGNITION LOSS, MEMORY LOSS OR VAGINAL DROUGHT IN SUSCEPTIBLE HOT BLOOD ANIMALS, INCLUDING HUMAN BEINGS, WHICH RESULT IN THE ADMINISTRATION OF A CERTAIN QUANTITY OF A SEXUAL STEROID PRECURSOR, PARTICULARLY DEHYDRELEDANDROTERONE (DHEA) AND AN ANTI-STROGEN OR SELECTIVE MODULATOR OF THE SELECTIVE STROGEN RECEPTOR, IN PARTICULAR OF BENZOPYRAN COMPOUNDS. The invention also relates to pharmaceutical compositions intended for the administration of one or more active agents and to one or more of the following useful for the invention.

MA34540A 2009-06-16 2010-06-16 Treatment of hot flashes of symptoms and night sweats with precursors of sexual steroids with selective estrogen receptor modifiers MA33434B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18754909P 2009-06-16 2009-06-16
US12/791,174 US20100317635A1 (en) 2009-06-16 2010-06-01 Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
PCT/CA2010/000898 WO2010145010A1 (en) 2009-06-16 2010-06-16 Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
MA33434B1 true MA33434B1 (en) 2012-07-03

Family

ID=43306950

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34540A MA33434B1 (en) 2009-06-16 2010-06-16 Treatment of hot flashes of symptoms and night sweats with precursors of sexual steroids with selective estrogen receptor modifiers

Country Status (20)

Country Link
US (4) US20100317635A1 (en)
EP (3) EP2442807A4 (en)
JP (4) JP2012530074A (en)
KR (10) KR20170138584A (en)
CN (3) CN102458404A (en)
AR (1) AR077119A1 (en)
AU (1) AU2010262722A1 (en)
BR (1) BRPI1011561A2 (en)
CA (2) CA2765446A1 (en)
CL (1) CL2011003172A1 (en)
EA (1) EA201200016A1 (en)
HK (1) HK1204550A1 (en)
IL (2) IL216963A (en)
MA (1) MA33434B1 (en)
MX (1) MX338290B (en)
NZ (1) NZ597583A (en)
SG (3) SG10201912379PA (en)
TW (1) TWI612044B (en)
WO (1) WO2010145010A1 (en)
ZA (1) ZA201109198B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
HUE025350T2 (en) 2011-07-19 2016-02-29 Pantarhei Bioscience Bv Tablet containing dehydroepiandrosterone (dhea)
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9018244B2 (en) 2011-12-16 2015-04-28 Olema Pharmaceuticals, Inc. Benzopyran compounds, compositions and uses thereof
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
WO2014008159A1 (en) * 2012-07-03 2014-01-09 The University Of North Carolina At Chapel Hill Selective estrogen receptor degraders for treatment of tamoxifen resistant tumors
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN103739456A (en) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 New derivative of 2-(p-((Z-4-chloro-1,2-diphenyl-1-butenyl) phenoxy) ethanol and application thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US10391071B2 (en) 2015-04-28 2019-08-27 Cutech Srl Compositions comprising valerian extracts
UA122348C2 (en) 2015-10-27 2020-10-26 Сан Фарма Адвансед Ресьорч Компані Лімітед Novel heterocyclic antiestrogens
KR102111792B1 (en) * 2016-03-25 2020-05-18 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드 Substituted indole compounds as estrogen receptor down-regulators
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
JP7168557B2 (en) * 2016-05-20 2022-11-09 アズール バイオテック，インコーポレーテッド Vaginal delivery system containing selective estrogen receptor modulators (SERMs) and uses thereof
MX2020002683A (en) * 2017-09-11 2020-09-25 Atossa Therapeutics Inc Topical compositions and methods for treatment.
CN111328280A (en) 2017-09-11 2020-06-23 阿托萨治疗学公司 Methods of making and using endoxifen
WO2022203097A1 (en) * 2021-03-24 2022-09-29 디어젠 주식회사 Composition, for preventing and treating central nervous system disorders, inhibiting overproduction of tdp-43 proteins by controlling atxn2 which is stress granule controller

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US60503A (en) 1866-12-18 Improvement in olaips foe gluing the tips on billiard cues
US3797444A (en) * 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
DE3333240A1 (en) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
CA1254514A (en) 1984-06-29 1989-05-23 Eugene Roberts Method for promoting nerve regeneration
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5154922A (en) * 1988-12-01 1992-10-13 Schering Corporation Compositions for transdermal delivery of estradiol
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
JP3441730B2 (en) 1993-01-19 2003-09-02 アンドルシェルシュ・インコーポレイテッド Dehydroepiandrosterone therapeutic applications and delivery systems
AU6513196A (en) 1995-07-11 1997-02-10 Ansaldo Volund A/S A stirling machine
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
IL124881A0 (en) 1996-01-11 1999-01-26 Novo Nordisk As Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
WO1997025035A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
WO1997032837A1 (en) 1996-03-06 1997-09-12 Sumitomo Pharmaceuticals Co., Ltd. Nonsteroidal estrogen derivatives
NZ314601A (en) 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6150381A (en) 1998-06-09 2000-11-21 R.J. Reynolds Tobacco Company Methods of treating microbial infection and therapeutic formulations therefor
HUP0102483A3 (en) * 1998-06-11 2002-11-28 Endorech Inc Sainte Foy Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
JP2003501390A (en) * 1999-06-04 2003-01-14 ザ ジュネラル ホスピタル コーポレーション Pharmaceutical formulations for treating postmenopausal and menopausal women, and uses thereof
HU230543B1 (en) * 1999-07-06 2016-11-28 Endorecherche, Inc. Medicament useful for treating and/or suppressing weight gain
WO2001026651A2 (en) 1999-10-14 2001-04-19 Endorecherche, Inc. Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
KR20020073566A (en) * 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 Selective estrogen receptor modulators in combination with estrogens
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
EP1501512A4 (en) * 2002-04-30 2009-11-18 Merck & Co Inc 4-azasteroid derivatives as androgen receptor modulators
RU2005113238A (en) 2002-10-01 2006-01-20 Дайниппон Фармасьютикал Ко., Лтд. (JP) SPIRAL COMPOUNDS CONTAINING THEIR MEDICINAL COMPOSITIONS AND INTERMEDIATE COMPOUNDS OF THE SPECIFIED COMPOUNDS
US20040121991A1 (en) 2002-12-20 2004-06-24 Araneo Barbara A. Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers
PE20050928A1 (en) 2003-11-21 2005-11-08 Schering Corp THERAPEUTIC COMBINATIONS OF ANTI-IGFR1 ANTIBODY
BRPI0506721A (en) * 2004-01-22 2007-05-02 Lilly Co Eli compound or an acid addition salt thereof
CN1997374A (en) * 2004-06-23 2007-07-11 默克公司 Estrogen receptor modulators
AU2005297367B2 (en) * 2004-10-20 2010-02-04 Myriel Pharmaceuticals, Llc Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
JP2009521408A (en) * 2005-12-02 2009-06-04 サートリス ファーマシューティカルズ， インコーポレイテッド Modulator of Cdc2-like kinase (CLK) and method of use thereof
CN101489563A (en) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
AU2012204083C1 (en) 2007-08-10 2015-02-05 Myriel Pharmaceuticals, Llc DHEA compositions for treating menopause
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM

Also Published As

Publication number Publication date
KR20190025752A (en) 2019-03-11
US10342805B2 (en) 2019-07-09
IL248245A0 (en) 2016-11-30
EP2442807A4 (en) 2013-06-26
KR20210048609A (en) 2021-05-03
MX338290B (en) 2016-04-07
JP2016029101A (en) 2016-03-03
US20190269696A1 (en) 2019-09-05
CA2893236A1 (en) 2010-12-23
KR20200108505A (en) 2020-09-18
TW201100403A (en) 2011-01-01
NZ597583A (en) 2014-10-31
KR20170138584A (en) 2017-12-15
TWI612044B (en) 2018-01-21
SG10201705761YA (en) 2017-08-30
EA201200016A1 (en) 2012-08-30
KR20170078879A (en) 2017-07-07
US20130244989A1 (en) 2013-09-19
CA2765446A1 (en) 2010-12-23
HK1204550A1 (en) 2015-11-27
KR20190090088A (en) 2019-07-31
US20100317635A1 (en) 2010-12-16
EP3178480A1 (en) 2017-06-14
CN104352504A (en) 2015-02-18
SG10201912379PA (en) 2020-02-27
SG177497A1 (en) 2012-02-28
EP2442807A1 (en) 2012-04-25
WO2010145010A1 (en) 2010-12-23
MX2011013689A (en) 2012-04-02
ZA201109198B (en) 2012-08-29
BRPI1011561A2 (en) 2016-03-29
EP3682880A1 (en) 2020-07-22
AU2010262722A1 (en) 2012-01-19
US20190269697A1 (en) 2019-09-05
IL216963A0 (en) 2012-02-29
KR20160072269A (en) 2016-06-22
JP2012530074A (en) 2012-11-29
KR20150141195A (en) 2015-12-17
KR20140070650A (en) 2014-06-10
JP2018203785A (en) 2018-12-27
CN102458404A (en) 2012-05-16
CL2011003172A1 (en) 2012-05-25
KR20120097470A (en) 2012-09-04
JP2014088442A (en) 2014-05-15
AR077119A1 (en) 2011-08-03
IL216963A (en) 2017-12-31
US11452731B2 (en) 2022-09-27
CN107468695A (en) 2017-12-15

Similar Documents

Publication Publication Date Title
MA33434B1 (en) Treatment of hot flashes of symptoms and night sweats with precursors of sexual steroids with selective estrogen receptor modifiers
MA31694B1 (en) DHEA compositions for the treatment of menopause
MA33219B1 (en) SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
JP2009525985A5 (en)
AU2014268779A1 (en) Therapeutic and method of use
NZ599430A (en) A drug delivery system for the prevention of cerebral vasospasm
Ghazal et al. Perspective on hormone therapy 10 years after the WHI
Indusekhar et al. Hormonal management of premenstrual syndrome
Kim et al. Effects of DA‐9701, a novel prokinetic agent, on gastric accommodation in conscious dogs
PE20060368A1 (en) HORMONE CONTRACEPTIVE CONTAINING A COMBINATION OF ETHINYLESTRADIOL AND CHLORMADINONE ACETATE
CN102791688A (en) Estrogen receptor ligands
Khot et al. Clinical efficacy of Ayurveda treatment on polycystic ovarian syndrome
Harper Should dermatologists prescribe hormonal contraceptives for acne?
Sánchez-Borrego et al. Position of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patients
JP2006522833A5 (en)
Hajak et al. A 2-week efficacy and safety study of gaboxadol and zolpidem using electronic diaries in primary insomnia outpatients
Hugon‐Rodin et al. The future of women's contraception: stakes and modalities
AR061477A1 (en) METHODS TO USE A TIAZOL DERIVATIVE
JP2008525317A5 (en)
Williams et al. Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity
Johnson et al. Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms
Kim Behavioral intervention and anti-obesity drug therapy
JP2009545593A5 (en)
Pérez-Neri et al. Inhibitory effect of dehydroepiandrosterone on brain monoamine oxidase activity: in vivo and in vitro studies
Agarwal et al. Can subepididymal orchiectomy Re-emerge as the treatment of choice in patients with advanced prostatic carcinoma?